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ASSESSING THE IMPACT ON STAFF RESOURCE AND PATIENT
WAITING TIME OF A SWITCH FROM IV TO ORAL
CHEMOTHERAPY: TIME AND MOTION MODEL FOR HTAS
Taylor H1, Burcombe R1, Hill S2, Cadwallader S2, James R1
1Kent Oncology Centre, Maidstone, UK; 2Pierre Fabre Ltd,
Winchester, Hampshire, UK
OBJECTIVE: Capacity planning is an increasingly important
determinant of NHS service delivery, and will be employed by
NICE to assess the resource implications of new chemotherapy
(CT) treatments. Navelbineâ (vinorelbine) Oral is an orally
administered version of a NICE-approved IV CT. A time and
motion methodology evaluated the impact on pharmacy and
nursing time, and patient waiting, of a switch from IV to oral
CT in a Cancer Centre and Unit. METHODS: Three CT regi-
mens were compared: Navelbine IV d1 d8, gemcitabine IV d1
d8, and Navelbine Oral d1 d8, all q21d. IV CT always required
an outpatient visit; oral administration on d8 could take place
in the clinic or at home. Five administrations were measured 
for each regimen in each setting and 80% variance calculated.
Results were extrapolated to three cycles of treatment.
RESULTS: Administration of Navelbine Oral was less time con-
suming in both the Cancer Centre and Unit. Pharmacy time in
the Centre was reduced from 3h to 1h. The Cancer Unit was
able to dispense on site rather than rely on a remote compounder.
Nursing time was reduced from 6h to 1h 18mins in the Centre
and from 41/2 h to 36mins in the Unit. Total patient visit time
was reduced from 26h 18mins to 7h 39mins in the Centre and
from 12h 54mins to 9h in the Unit. CONCLUSIONS: Delivery
of oral CT is less resource intensive and time consuming than IV
CT and reduces overall patient waiting in hospital. A switch
from IV CT to Navelbine Oral, with home administration on d8,
resulted in a four-fold increase in the capacity of the day unit,
and a three-fold increase in the number of prescriptions prepared
by pharmacy. The methodology provides a quantitative measure
of comparative capacity that could be used as part of future
health technology assessments.
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APPLICATION OF AN ALGORITHM FOR DEFINING
RETROSPECTIVE COHORTS OF COLORECTAL CANCER
(CRC) PATIENTS TREATED WITH DIFFERENT FIRST-LINE
CHEMOTHERAPY REGIMENS +/- BEVACIZUMAB TO
ADMINISTRATIVE CLAIMS DATA
Cisternas MG1, Mrad R2, Noe LL1, Miller DP1, Guyan C1
1Ovation Research Group, Highland Park, IL, USA; 2F. Hoffmann-La
Roche Ltd, Basel, Switzerland
OBJECTIVES: To apply a previously described algorithm for
deﬁning cohorts of CRC patients treated with ﬁrst-line
chemotherapy agents +/- the targeted therapy bevacizumab to
an administrative health insurance claims database. METHODS:
Claims records for 717 patients newly diagnosed for CRC in
2003 or 2004 who initiated chemotherapy during 2004 were
extracted from a large U.S. health care claims database. By
applying a previously deﬁned algorithm (see “Development of
an algorithm for the identiﬁcation and classiﬁcation of colorec-
tal cancer (CRC) patients according to ﬁrst-line chemotherapy
+/- bevacizumab using administrative claims records”) these
patients were classiﬁed according to ﬁve, mutually exclusive,
ﬁrst-line chemotherapy regimens +/- bevacizumab. RESULTS:
Of the 717 patients identiﬁed, 709 (99%) could be assigned to
one of the ﬁrst-line chemotherapy categories: oxaliplatin (25%);
irinotecan+bolus 5-FU/LV (2%); irinotecan+infusional 5-FU/LV
(1%); irinotecan+5-FU/LV (bolus vs. infusion not distinguish-
able) (5%); and 5-FU/LV or capecitabine alone (66%). Each cat-
egory was further subdivided according to whether bevacizumab
was administered during the ﬁrst month of chemotherapy. Of the
97 patients with a J9999 (“antineoplastic drug not elsewhere
classiﬁed”) HCPCS claim in 2004, 12 had only one such claim
and therefore bevacizumab vs. cetuxmab could not be identiﬁed;
all but 2 of the remaining had their J9999 claims identiﬁed deﬁn-
itively. Seventy patients incurred a J9999 claim within their 
ﬁrst-line therapy: assignment to bevacizumab, cetuximab, and
unknown was 63, 1, and 6, respectively. Eighty patients (11%)
received second-line therapy. CONCLUSIONS: First-line
chemotherapies for CRC can be identiﬁed in health insurance
claims data through a careful examination of CPT, HCPCS, and
revenue center codes and the intervals between them. However,
distinguishing bolus vs. infusion regimens is challenging due to
inconsistent coding of ambulatory pump and IV push claims.
Newly approved agents billed under a “not otherwise classiﬁed”
code can be distinguished if their costs or intervals of adminis-
tration differ substantially.
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DEVELOPMENT OF AN ALGORITHM FOR THE
IDENTIFICATION AND CLASSIFICATION OF COLORECTAL
CANCER (CRC) PATIENTS ACCORDING TO FIRST-LINE
CHEMOTHERAPY +/- BEVACIZUMAB,AND INITIATION OF
SECOND-LINE THERAPY USING ADMINISTRATIVE CLAIMS
RECORDS
Cisternas MG1, Mrad R2, Noe LL1, Miller DP1, Guyan C1
1Ovation Research Group, Highland Park, IL, USA; 2F. Hoffmann-La
Roche Ltd, Basel, Switzerland
OBJECTIVES: To develop an algorithm for deﬁning cohorts of
newly diagnosed CRC patients according to ﬁrst- and second-
line chemotherapy regimen and the use of bevacizumab using
administrative claims records. METHODS: A three-step process
was used to create algorithms for ﬁrst-line chemotherapy regi-
mens and the use of the anti-angiogenic agent bevacizumab: 1)
a literature review and consultation with clinicians was per-
formed to deﬁne common treatment patterns in CRC (medica-
tion and dosage, modes and timing of administrations); 2) coding
of chemotherapy agents and modes of administration were
mapped through review of CPT, HCPCS, and UB-92 revenue
center coding guides; 3) coding of agents, modes of administra-
tion, and medication dose by cost proxy was reﬁned through
empirical review of all claims associated with chemotherapy 
and CRC diagnoses in a sample of the data. RESULTS: Patients
were identiﬁed as having newly-diagnosed CRC during a quali-
fying period if they had an ICD-9-CM claim for malignant 
CRC preceded by a 12-month period without any CRC claims.
Five ﬁrst-line chemotherapy regimens were identiﬁed: oxali-
platin+5-FU/LV, irinotecan+bolus 5-FU/LV, irinotecan+infusional
5-FU/LV, irinotecan+5-FU/LV (bolus vs. infusion not distin-
guishable), and 5-FU/LV or capecitabine alone (without oxali-
platin or irinotecan). Bevacizumab did not have a speciﬁcally
assigned billing code in 2004 but could be differentiated from
another agent approved for the treatment of metastatic CRC in
the second line—cetuximab—through examination of the fre-
quency of administration and medication cost. The initiation of
second-line therapy was deﬁned as change to/addition of any of
the following agents thirty days after starting ﬁrst-line therapy:
irinotecan, oxaliplatin, or cetuximab. CONCLUSIONS: Retro-
spective cohorts of CRC patients treated with different
chemotherapy agents and bevacizumab can be identiﬁed in
claims data through examination of ICD-9-CM, CPT, HCPCS,
and revenue center codes, as well as frequency of administration
and cost of chemotherapy.
